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Keith Joung, Dan Voytas and Joanne Kamens share
insights into how the genome editing field was
advanced by early access to biological resources and
the role in this process that plasmid repositories play.Changing science one plasmid at a time
The ability to build upon the findings of others is one of
the cornerstones of science. We can, however, effectively
use the achievements of our predecessors only if the
data and the resources that they generated are easily
accessible to us. In genomics, data deposition is almost a
given, data formats and sharing frameworks are more
and more standardized, and while data quality control is
still necessary, it is not as time- and resource-consuming
as similar processes for physical materials. Which is
where public repositories of biological resources come
in, to help the researchers cut through the red tape of
material transfer agreements, and to ensure the quality
of those resources. A number of such repositories exist
to support molecular biology researchers, ranging from
institutional, such as Harvard PlasmID Database or
DNASU Plasmid Repository, through large state-funded
ones, such as the National Institutes of Health’s PlasmID
or Mammalian Gene Collection, to independent organi-
zations, such as Addgene.
Addgene is a nonprofit plasmid repository that was
founded in 2004 to overcome the obstacles with plasmid
sharing. Shortly after its conception, Addgene launched
a fruitful collaboration with the Zinc Finger Consortium,
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velopment of genome editing technologies. Here, we ask
two founding members of the Zinc Finger Consortium,
Keith Joung and Dan Voytas, and Addgene’s current
Executive Director, Joanne Kamens, about this collab-
oration and its influence on the genome editing field.What inspired the foundation of Addgene? Why do we
need this repository rather than researchers just
requesting plasmids from other researchers?
Joanne Kamens: Addgene’s scientific founder, Melina
Fan, was inspired by the almost universal experience of
requesting published reagents and getting no response
or the wrong plasmid. The waste of the vast resources
stuck in lab freezers is what drives us every day.
Addgene offers so many services and advantages over
standard “walk down the hall” sharing. For starters,
quality control and bar-coding of each plasmid ensures
scientists get what they request. We are always curating
with the help of our huge sharing community.
Dan Voytas: It is a considerable time and resource
sink to send plasmids and reagents to many different
investigators. The effort involves preparing and sending
out materials as well as completing material transfer
agreements. The burden becomes impossible when the
reagents are highly sought after. There is no way we
would have the resources to send out the 1500 or so
TALEN kits that were requested from Addgene. No
single lab could handle the tsunami of requests for
CRISPR/Cas reagents.What impact has Addgene had on the genome editing
field?
Dan Voytas: For many years, the field was frustrated
by lack of efficient reagents to achieve targeted chromo-
some breaks. Efforts initially focused on zinc finger nu-
cleases, then TALENs, then CRISPR/Cas. Each platform
achieved new levels of efficacy. However, in order for the
technology to be truly useful to the typical molecularis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Joung et al. Genome Biology  (2015) 16:255 Page 2 of 4biologist/geneticist, each new improvement had to be
quickly disseminated. Addgene filled that need.
Keith Joung: Addgene played a very large role in
enabling widespread distribution of genome editing re-
agents. When we started the Zinc Finger Consortium in
2005, a major goal of ours was to make the technology
available to all academics interested in practicing it.
Addgene enabled us to do this efficiently and effectively.
I believe that the tone and practice we established early
on in the field then led to others following suit as the
TALEN and CRISPR/Cas9 technologies emerged.
Are there any other fields where the repository had a big
impact?
Joanne Kamens: Addgene has impacted a wide variety
of fields by not only helping to store and distribute plas-
mids, but also creating a community resource for proto-
cols, educational materials, and science news. A few
examples of plasmid collections and fields that Addgene
has impacted are shown in Fig. 1. We recently updated
our Viral Vector web pages to help scientists find com-
monly used envelope, packaging, and transfer plasmids,
answer FAQs, and direct scientists to reliable protocols.
Since we began creating our lentivirus resources, our
web pages and related blog posts have been viewed over
325,000 times.
What are some of the unique characteristics of the
Addgene repository?
Joanne Kamens: Three of the most unique characteris-
tics of Addgene are the diversity of the collection, the level
of customer service, and its unique, nonprofit model. TheFig. 1 Examples of plasmid collections impacted by Addgenecollection’s diversity makes us a good place to start when
looking for any plasmid. Researchers working in every or-
ganism and research field are depositing to Addgene. We
recently opened a customer support office near London to
enable us to more easily serve the international commu-
nity of scientists. I say with some pride that Addgene’s
customer service is unparalleled. We answer over 4500
emails and over 1000 phone calls each month. Most are
logistics questions, but hundreds are technical service
questions about plasmid selection or even “Why do my
gel bands look like this?” Last, Addgene’s unique business
model ensures that we are not dependent on grants or
university support. This allows us to focus on service to
the community. Also, as a nonprofit, we can make every
decision based on fulfilling our mission: to accelerate
research and discovery by improving access to useful
research materials and information.
Addgene’s resource has been steadily growing in the
decade of its existence, but recent years have seen an
especially large increase of submissions (from 25,000 in
2012, to 40,000 in 2015). Can you explain the reasons for
this phenomenon?
Joanne Kamens: In early 2013 Addgene hit a tipping
point. That year Addgene was able to dramatically in-
crease outreach activities (Fig. 2). Additionally, it was
the year when most of the labs doing the early work on
CRISPR/Cas9-mediated genome engineering committed
to making their plasmids easily accessible via Addgene.
Addgene’s increased visibility in the research community
was driven by our own team raising awareness and by
scientists finding Addgene because they were interested
Fig. 2 Growth of the Addgene resource
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the scientists who deposited with Addgene before publi-
cation so plasmid numbers could be included in those
first CRISPR papers. Once scientists find us, our great
plasmid and information resources keep them engaged.
The Zinc Finger Consortium has been collaborating with
Addgene almost from its very beginning. Can you tell us
how this collaboration started?
Dan Voytas: Keith learned about my efforts (initially
unsuccessful) to make ZFNs for the targeted modifica-
tion of plant genomes. He suggested that we work to-
gether to come up with a reliable, easy-to-use platform
to make effective ZFNs. I invited Keith to visit me atIowa State University, and during that meeting we
crafted the idea for establishing a Zinc Finger Consor-
tium to achieve this end. We felt from the onset that the
tools of genome engineering should be broadly avail-
able. Hence, we began a relationship with Addgene from
the onset to make the reagents available.
Keith Joung: As Dan says, the Zinc Finger Consor-
tium was born in October 2005 during a meeting he and
I had at Iowa State University. We knew that we wanted
to make the reagents we would be generating available
to academics but I have to admit that we didn’t really
know in the early days exactly how we would do it.
Around the same time as we were beginning to plan for
distributing our initial set of reagents, I was contacted
by someone from Addgene who wanted to tell me about
their services. I remember calling Dan after that meeting
and saying to him that I thought we had an answer for
how to distribute the reagents. We committed our initial
set of plasmids to Addgene and then had a productive
relationship going forward for all of our future reagents.
What advice would you give to researchers who would
like to start a similar type of collaboration with Addgene?
Joanne Kamens: We are extremely eager to collaborate
with all kinds of labs, consortia, and communities to
create special collections. The Zinc Finger Consortium
really helped us to get the ball rolling and serves as a
model for how Addgene can work with groups to pro-
mote their useful reagents. Call us anytime and we will
assign an Addgene scientist to your project. We can’t
possibly have in-house expertise in all the areas, so we
really appreciate having thought leaders who are familiar
with the science helping us bring new collections online.
The Addgene Special Collections page gives a taste of
the many different ways scientists have worked with us
to deposit collections, encourage their colleagues to de-
posit, and to provide supporting information for the com-
munity (https://www.addgene.org/special-collections/).
We expect to see a growing number of screening studies
utilizing CRISPR/Cas technology. Given the numbers of
sgRNAs used in a screen like this, do you expect a large
increase of depositions to Addgene? Will it be scalable
enough to handle those?
Joanne Kamens: Addgene has been actively preparing
to take larger plasmid collections and screening libraries.
We are currently optimizing the technology in house
to amplify pooled libraries to ensure an endless supply
of high-quality CRISPR libraries will be available to an
increasing number of interested laboratories. Pooled
libraries are distributing very well and more are being
deposited. Last year, Dr. Michael Davidson from Florida
State University contacted us. He wanted Addgene to take
his entire 3000 plasmid fluorescent protein collection as a
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other deposit we had taken especially because the utility
of this amazing collection meant that it needed to be able
to be distributed individually, not just as a full collection.
We learned a lot getting this collection online and are in
the process of automating many of our processes to make
sure we can accept collections of any size.
Do you think similar repositories are needed for other
types of materials? If so, what advice would you give to
people wanting to start one?
Dan Voytas: It is unclear to me if multiple repositories
are necessary. Technology changes quickly, and as long
as one repository is able to adapt to meet the commu-
nity’s needs, that should suffice.
Keith Joung: As genome editing nucleases continue to
be widely adopted, it may become important to establish
repositories for cells and organisms modified by these
technologies. Although I suppose that it might also be-
come so simple to generate these cells and organisms
that doing so may be unnecessary as well. It will be
exciting to see what happens moving forward.
Joanne Kamens: I went back to Addgene’s founders
to get expert input on this one. Melina Fan says, “When
starting a repository, trust is your most important asset.
To build trust, you need to meticulously track your sam-
ples, conduct vigorous quality control, and provide ex-
cellent scientific support. To seed the repository, actively
pursue the samples that you believe are important for
the research community to share.” Benjie Chen adds,
“Come up with a plan to be self-sustaining, make sure
you are being realistic to yourself and the model is
attainable. Then, commit to it and work on it, and be
persistent even when times are tough.” Finally, Ken Fan
offers this advice, “Bio-repositories can be expensive to
launch and to operate. Before starting a new repository,
make sure to evaluate the short-term and long-term po-
tential for financial self-sustainability, including start-up
expenses, expected revenue and operating costs. Also,
given the challenges with building a new repository,
make sure your mission and personal objectives are clear
and focused.” I will add a piece of my own advice: hire
great people who enjoy working together. Addgene’s
most valuable assets are the talented Addgenies who
work hard to serve the scientific community.
What lies in the future for reagent repositories in general
and Addgene in particular?
Dan Voytas: In the early days of the genome engineer-
ing revolution, we witnessed the development of tools/
reagents that are broadly useful across diverse organ-
isms. I anticipate that the next phase will involve the
development and dissemination of reagents and vectors
that achieve effective targeted modification in a subsetof organisms (plants, insects, vertebrates). The demand
for a given, specialized reagent will be less; however, ac-
cess to these reagents will be very important for advan-
cing science in many research communities.
Keith Joung: It is gratifying to see the model of shar-
ing reagents so widely practiced now by the genome
editing field. When Dan and I started doing this with
the Zinc Finger Consortium almost a decade ago, I know
we believed that it was important to do but I don’t think
we quite appreciated how much of an impact our actions
would have in setting the tone and approach for the lar-
ger field.
Joanne Kamens: We recently moved into a new, lar-
ger facility which will allow us to expand in new direc-
tions. Part of our new space is being outfitted as a BL2+
laboratory to enable mammalian cell work at Addgene
for the first time. We will also be adding a new research
team to pursue new projects that require more technical
benchwork than we do now. Addgene provides an enor-
mous amount of technical customer service. With this
new lab space, our scientists will be able to test out pro-
tocols and reagents, allowing us to better support the
community with protocol and reagent advice. Another
project we are pursuing is being able to offer our plas-
mids in different formats. I hope to be able to tell you
much more about this in 2016. We are incredibly excited
to be in a position to consider new ways to help scien-
tists accelerate their research.
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